Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Sonja Zweegman"'
Publikováno v:
Cancer & Metabolism, Vol 5, Iss 1, Pp 1-12 (2017)
Abstract Background The proteasome inhibitor bortezomib (BTZ) is successfully applied in the treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of resistance. Metabolic alterations play an important role in ca
Externí odkaz:
https://doaj.org/article/c8fce22ac9cc493fbb649139a07638da
Autor:
Denise Niewerth, Gertjan J. L. Kaspers, Gerrit Jansen, Johan van Meerloo, Sonja Zweegman, Gaye Jenkins, James A. Whitlock, Stephen P. Hunger, Xiaomin Lu, Todd A. Alonzo, Peter M. van de Ven, Terzah M. Horton, Jacqueline Cloos
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-9 (2016)
Abstract Background Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (AL
Externí odkaz:
https://doaj.org/article/172eb78a2bea491c981a5e1211f1352f
Autor:
Cathelijne Fokkema, Phillipe Moreau, Bronno Van der Holt, Jérôme Lambert, Mark Van Duin, Ruth Wester, Joost L.M. Jongen, Pieter A. Van Doorn, Sophie Godet, Kon Siong Jie, Olivier Fitoussi, Michel Delforge, Awa Keita-Manta, Odile Luycx, Tom Cupedo, Niels W.C.J. Van de Donk, Sonja Zweegman, Jessica T. Vermeulen, Pieter Sonneveld, Annemiek Broijl
Publikováno v:
Haematologica, 107(7), 1726-1730. Ferrata Storti Foundation
Fokkema, C, Moreau, P, van der Holt, B, Lambert, J R, van Duin, M, Wester, R, Jongen, J L M, van Doorn, P A, Godet, S, Jie, K, Fitoussi, O, Delforge, M, Keita-Manta, A, Luycx, O, Cupedo, T, van de Donk, N W C J, Zweegman, S, Vermeulen, J T, Sonneveld, P & Broijl, A 2022, ' Treatment emergent peripheral neuropathy in the CASSIOPEIA trial ', Haematologica, vol. 107, no. 7, pp. 1726-1730 . https://doi.org/10.3324/haematol.2021.280567
Fokkema, C, Moreau, P, van der Holt, B, Lambert, J R, van Duin, M, Wester, R, Jongen, J L M, van Doorn, P A, Godet, S, Jie, K, Fitoussi, O, Delforge, M, Keita-Manta, A, Luycx, O, Cupedo, T, van de Donk, N W C J, Zweegman, S, Vermeulen, J T, Sonneveld, P & Broijl, A 2022, ' Treatment emergent peripheral neuropathy in the CASSIOPEIA trial ', Haematologica, vol. 107, no. 7, pp. 1726-1730 . https://doi.org/10.3324/haematol.2021.280567
Not available. ispartof: HAEMATOLOGICA vol:107 issue:7 pages:1726-1730 ispartof: location:Italy status: published
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f37b179d5009da57356c0fed285b7ea3
https://research.vumc.nl/en/publications/19496033-1c64-462b-a9fa-235b2cb63de5
https://research.vumc.nl/en/publications/19496033-1c64-462b-a9fa-235b2cb63de5
Autor:
Sonja Zweegman, Anne T. Gelderloos, Esther C.W. Breij, Inger S. Nijhof, Tuna Mutis, Hilma J. van der Horst, Marije B. Overdijk, Martine E D Chamuleau
Publikováno v:
van der Horst, H J, Gelderloos, A T, Chamuleau, M E D, Breij, E C W, Zweegman, S, Nijhof, I S, Overdijk, M B & Mutis, T 2021, ' Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma ', Blood, vol. 5, no. 8, pp. 2165-2172 . https://doi.org/10.1182/BLOODADVANCES.2020003731
Blood Adv
Blood, 5(8), 2165-2172. American Society of Hematology
Blood Adv
Blood, 5(8), 2165-2172. American Society of Hematology
Apoptosis induction by death receptor (DR)-specific agonistic antibodies is a potentially effective antitumor therapy. Nonetheless, to date, all conventional DR-targeting antibodies that induce apoptosis via FcγR-dependent DR clustering failed to sh
Autor:
Jesús F. San-Miguel, U. Mey, Mario Boccadoro, Thierry Facon, Roman Hájek, P. Moreau, M.V. Mateos, E. Terpos, M.A. Dimopoulos, Michele Cavo, Fredrik Schjesvold, H. Goldschmidt, Gordon Cook, Michel Delforge, Sonja Zweegman, H. Einsele, Pieter Sonneveld
Publikováno v:
EHA Guidelines Committee & ESMO Guidelines Committee 2021, ' Multiple myeloma : EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † ', Annals of Oncology, vol. 32, no. 3, pp. 309-322 . https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology, 32(3), 309-322. Oxford University Press
Annals of Oncology, 32(3), 309-322. Elsevier Ltd.
Dimopoulos, M A, Moreau, P, Terpos, E, Mateos, M V, Zweegman, S, Cook, G, Delforge, M, Hájek, R, Schjesvold, F, Cavo, M, Goldschmidt, H, Facon, T, Einsele, H, Boccadoro, M, San-Miguel, J, Sonneveld, P & Mey, U 2021, ' Multiple Myeloma : EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up ', HemaSphere . https://doi.org/10.1097/HS9.0000000000000528
HemaSphere
Annals of Oncology, 32(3), 309-322. Oxford University Press
Annals of Oncology, 32(3), 309-322. Elsevier Ltd.
Dimopoulos, M A, Moreau, P, Terpos, E, Mateos, M V, Zweegman, S, Cook, G, Delforge, M, Hájek, R, Schjesvold, F, Cavo, M, Goldschmidt, H, Facon, T, Einsele, H, Boccadoro, M, San-Miguel, J, Sonneveld, P & Mey, U 2021, ' Multiple Myeloma : EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up ', HemaSphere . https://doi.org/10.1097/HS9.0000000000000528
HemaSphere
ispartof: HEMASPHERE vol:5 issue:2 ispartof: location:United States status: published
Autor:
Saskia K. Klein, Gerard M. J. Bos, Sonja Zweegman, Mark-David Levin, Niels W.C.J. van de Donk, Kristine A. Frerichs, Monique C. Minnema, Marie José Kersten, Annemiek Broijl, Inger S. Nijhof, Tuna Mutis, Pieter Sonneveld, Patty W C Maas-Bosman, Christie P. M. Verkleij
Publikováno v:
Blood advances, 5(23), 5128-5139. American Society of Hematology
Blood, 5, 5128-5139. American Society of Hematology
Blood advances, 5, 5128-5139. American Society of Hematology
Blood Advances, 5, 5128-5139. AMER SOC HEMATOLOGY
Blood advances, 5(23), 5128-5139. The American Society of Hematology
Frerichs, K A, Minnema, M C, Levin, M-D, Broijl, A, Bos, G M J, Kersten, M J, Mutis, T, Verkleij, C P M, Nijhof, I S, Maas-Bosman, P W C, Klein, S K, Zweegman, S, Sonneveld, P & van de Donk, N W C J 2021, ' Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma ', Blood, vol. 5, pp. 5128-5139 . https://doi.org/10.1182/bloodadvances.2021005220
Blood, 5, 5128-5139. American Society of Hematology
Blood advances, 5, 5128-5139. American Society of Hematology
Blood Advances, 5, 5128-5139. AMER SOC HEMATOLOGY
Blood advances, 5(23), 5128-5139. The American Society of Hematology
Frerichs, K A, Minnema, M C, Levin, M-D, Broijl, A, Bos, G M J, Kersten, M J, Mutis, T, Verkleij, C P M, Nijhof, I S, Maas-Bosman, P W C, Klein, S K, Zweegman, S, Sonneveld, P & van de Donk, N W C J 2021, ' Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma ', Blood, vol. 5, pp. 5128-5139 . https://doi.org/10.1182/bloodadvances.2021005220
The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We have previously shown that all-trans retinoic acid (ATRA) upregulates CD38 expression and reverts daratumumab-resistance ex vivo. We therefore evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1300c789f6fb8b2ff67d082a73870fc2
https://pure.eur.nl/en/publications/27f5b501-5187-486c-80a3-6a54af2e2834
https://pure.eur.nl/en/publications/27f5b501-5187-486c-80a3-6a54af2e2834
Autor:
Michele Cavo, Francesca Gay, Meral Beksac, Lucia Pantani, Maria Teresa Petrucci, Meletios A Dimopoulos, Luca Dozza, Bronno van der Holt, Sonja Zweegman, Stefania Oliva, Vincent H J van der Velden, Elena Zamagni, Giuseppe A Palumbo, Francesca Patriarca, Vittorio Montefusco, Monica Galli, Vladimir Maisnar, Barbara Gamberi, Markus Hansson, Angelo Belotti, Ludek Pour, Paula Ypma, Mariella Grasso, Alexsandra Croockewit, Stelvio Ballanti, Massimo Offidani, Iolanda D Vincelli, Renato Zambello, Anna Marina Liberati, Niels Frost Andersen, Annemiek Broijl, Rossella Troia, Anna Pascarella, Giulia Benevolo, Mark-David Levin, Gerard Bos, Heinz Ludwig, Sara Aquino, Anna Maria Morelli, Ka Lung Wu, Rinske Boersma, Roman Hajek, Marc Durian, Peter A von dem Borne, Tommaso Caravita di Toritto, Thilo Zander, Christoph Driessen, Giorgina Specchia, Anders Waage, Peter Gimsing, Ulf-Henrik Mellqvist, Marinus van Marwijk Kooy, Monique Minnema, Caroline Mandigers, Anna Maria Cafro, Angelo Palmas, Susanna Carvalho, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld
Publikováno v:
Lancet Haematology, 7, 6, pp. E456-E468
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, von dem Borne, P A, Caravita di Toritto, T, Driessen, C, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U H, van Marwijk Kooy, M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, ' Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study ', The Lancet Haematology, vol. 7, no. 6, pp. e456-e468 . https://doi.org/10.1016/S2352-3026(20)30099-5
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M-D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, Borne, P A V D, di Toritto, T C, Zander, T, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U-H, Kooy, M V M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, ' Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study ', The Lancet Haematology, vol. 7, no. 6, pp. E456-E468 . https://doi.org/10.1016/S2352-3026(20)30099-5
The Lancet Haematology, 7(6), e456-e468. Lancet Publishing Group
The Lancet Haematology, 7(6), E456-E468. ELSEVIER SCI LTD
The Lancet Haematology, 7(6), E456-E468. Lancet Publishing Group
Lancet Haematology, 7, E456-E468
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, von dem Borne, P A, Caravita di Toritto, T, Driessen, C, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U H, van Marwijk Kooy, M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, ' Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study ', The Lancet Haematology, vol. 7, no. 6, pp. e456-e468 . https://doi.org/10.1016/S2352-3026(20)30099-5
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M-D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, Borne, P A V D, di Toritto, T C, Zander, T, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U-H, Kooy, M V M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, ' Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study ', The Lancet Haematology, vol. 7, no. 6, pp. E456-E468 . https://doi.org/10.1016/S2352-3026(20)30099-5
The Lancet Haematology, 7(6), e456-e468. Lancet Publishing Group
The Lancet Haematology, 7(6), E456-E468. ELSEVIER SCI LTD
The Lancet Haematology, 7(6), E456-E468. Lancet Publishing Group
Lancet Haematology, 7, E456-E468
Background The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared aut
Autor:
Pieter Sonneveld, Meletios A. Dimopoulos, Meral Beksac, Bronno van der Holt, Sara Aquino, Heinz Ludwig, Sonja Zweegman, Thilo Zander, Elena Zamagni, Ruth Wester, Roman Hajek, Lucia Pantani, Luca Dozza, Francesca Gay, AnneMaria Cafro, Luca De Rosa, Annamaria Morelli, Henrik Gregersen, Nina Gulbrandsen, Petra Cornelisse, Rosella Troia, Stefania Oliva, Vincent van de Velden, KaLung Wu, Paula F. Ypma, Gerard Bos, Mark-David Levin, Luca Pour, Christoph Driessen, Annemiek Broijl, Alexandra Croockewit, Monique C. Minnema, Anders Waage, Cecilie Hveding, Niels W. C. J. van de Donk, Massimo Offidani, Giuseppe A. Palumbo, Andrew Spencer, Mario Boccadoro, Michele Cavo
Publikováno v:
Sonneveld, P, Dimopoulos, M A, Beksac, M, van der Holt, B, Aquino, S, Ludwig, H, Zweegman, S, Zander, T, Zamagni, E, Wester, R, Hajek, R, Pantani, L, Dozza, L, Gay, F, Cafro, A M, De Rosa, L, Morelli, A, Gregersen, H, Gulbrandsen, N, Cornelisse, P, Troia, R, Oliva, S, van de Velden, V, Wu, K L, Ypma, P F, Bos, G, Levin, M D, Pour, L, Driessen, C, Broijl, A, Croockewit, A, Minnema, M C, Waage, A, Hveding, C, van de Donk, N W C J, Offidani, M, Palumbo, G A, Spencer, A, Boccadoro, M & Cavo, M 2021, ' Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 32, pp. 3613-3622 . https://doi.org/10.1200/JCO.21.01045
Journal of Clinical Oncology, 39, 32, pp. 3613-3622
Journal of Clinical Oncology, 39, 3613-3622
Journal of Clinical Oncology, 39(32), 3613-3622. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(32), 3613-3622. American Society of Clinical Oncology
Sonneveld, P, Dimopoulos, M A, Beksac, M, van der Holt, B, Aquino, S, Ludwig, H, Zweegman, S, Zander, T, Zamagni, E, Wester, R, Hajek, R, Pantani, L, Dozza, L, Gay, F, Cafro, A, De Rosa, L, Morelli, A, Gregersen, H, Gulbrandsen, N, Cornelisse, P, Troia, R, Oliva, S, van de Velden, V, Wu, K, Ypma, P F, Bos, G, Levin, M-D, Pour, L, Driessen, C, Broijl, A, Croockewit, A, Minnema, M C, Waage, A, Hveding, C, van de Donk, N W C J, Offidani, M, Palumbo, G A, Spencer, A, Boccadoro, M & Cavo, M 2021, ' Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma ', Journal of Clinical Oncology, vol. 39, no. 32, JCO2101045, pp. 3613-3622 . https://doi.org/10.1200/JCO.21.01045
Journal of Clinical Oncology, 39, 32, pp. 3613-3622
Journal of Clinical Oncology, 39, 3613-3622
Journal of Clinical Oncology, 39(32), 3613-3622. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(32), 3613-3622. American Society of Clinical Oncology
Sonneveld, P, Dimopoulos, M A, Beksac, M, van der Holt, B, Aquino, S, Ludwig, H, Zweegman, S, Zander, T, Zamagni, E, Wester, R, Hajek, R, Pantani, L, Dozza, L, Gay, F, Cafro, A, De Rosa, L, Morelli, A, Gregersen, H, Gulbrandsen, N, Cornelisse, P, Troia, R, Oliva, S, van de Velden, V, Wu, K, Ypma, P F, Bos, G, Levin, M-D, Pour, L, Driessen, C, Broijl, A, Croockewit, A, Minnema, M C, Waage, A, Hveding, C, van de Donk, N W C J, Offidani, M, Palumbo, G A, Spencer, A, Boccadoro, M & Cavo, M 2021, ' Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma ', Journal of Clinical Oncology, vol. 39, no. 32, JCO2101045, pp. 3613-3622 . https://doi.org/10.1200/JCO.21.01045
PURPOSE To address the role of consolidation treatment for newly diagnosed, transplant eligible patients with multiple myeloma in a controlled clinical trial. PATIENTS AND METHODS The EMN02/HOVON95 trial compared consolidation treatment with two cycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d062212186695d034b375b07fa82bfad
https://research.vumc.nl/en/publications/2b32098e-ca08-476c-9883-09664c6f97bc
https://research.vumc.nl/en/publications/2b32098e-ca08-476c-9883-09664c6f97bc
Autor:
Matthijs Westerman, Bertrand Arnulf, Frédérique Kuhnowski, Tahamtan Ahmadi, Annemiek Broijl, Lotfi Benboubker, Marie-Christiane Vekemans, Sonja Zweegman, Xavier Leleu, Maria Krevvata, Cyrille Touzeau, Veronique Vanquickelberghe, Hélène Caillon, Denis Caillot, Ke Zhang, Soraya Wuilleme, Pieter Sonneveld, Michel Delforge, Mark-David Levin, Jean-Richard Eveillard, Jill Corre, Aurore Perrot, Philippe Moreau, Mohamad Mohty, Nathalie Meuleman, Anne-Marie Stoppa, Jessica Vermeulen, Kon-Siong Jie, Saskia K. Klein, Tobias Kampfenkel, Fritz Offner, Thierry Facon, Hervé Avet-Loiseau, Chantal Doyen, Frédérique Orsini-Piocelle, Cécile Sonntag, Murielle Roussel, Carla de Boer, Jean-Pierre Marolleau, Reda Garidi, Thomas Dejoie, Mourad Tiab, Cyrille Hulin, Lionel Karlin, Margaret Macro, Jean Fontan, Sanjay Vara, Jérôme J. Lambert, Niels W.C.J. van de Donk, Marie C. Béné, Martine Escoffre-Barbe, Karim Belhadj
Publikováno v:
The Lancet Oncology, 22(10), 1378-1390. Lancet Publishing Group
Moreau, P, Hulin, C, Perrot, A, Arnulf, B, Belhadj, K, Benboubker, L, Béné, M C, Zweegman, S, Caillon, H, Caillot, D, Corre, J, Delforge, M, Dejoie, T, Doyen, C, Facon, T, Sonntag, C, Fontan, J, Mohty, M, Jie, K S, Karlin, L, Kuhnowski, F, Lambert, J, Leleu, X, Macro, M, Orsini-Piocelle, F, Roussel, M, Stoppa, A M, van de Donk, N W C J, Wuillème, S, Broijl, A, Touzeau, C, Tiab, M, Marolleau, J P, Meuleman, N, Vekemans, M C, Westerman, M, Klein, S K, Levin, M D, Offner, F, Escoffre-Barbe, M, Eveillard, J R, Garidi, R, Ahmadi, T, Krevvata, M, Zhang, K, de Boer, C, Vara, S, Kampfenkel, T, Vanquickelberghe, V, Vermeulen, J, Avet-Loiseau, H & Sonneveld, P 2021, ' Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 10, pp. 1378-1390 . https://doi.org/10.1016/S1470-2045(21)00428-9
The Lancet. Oncology, Vol. 22, no. 10, p. 1378-1390 (2021)
Moreau, P, Hulin, C, Perrot, A, Arnulf, B, Belhadj, K, Benboubker, L, Béné, M C, Zweegman, S, Caillon, H, Caillot, D, Corre, J, Delforge, M, Dejoie, T, Doyen, C, Facon, T, Sonntag, C, Fontan, J, Mohty, M, Jie, K S, Karlin, L, Kuhnowski, F, Lambert, J, Leleu, X, Macro, M, Orsini-Piocelle, F, Roussel, M, Stoppa, A M, van de Donk, N W C J, Wuillème, S, Broijl, A, Touzeau, C, Tiab, M, Marolleau, J P, Meuleman, N, Vekemans, M C, Westerman, M, Klein, S K, Levin, M D, Offner, F, Escoffre-Barbe, M, Eveillard, J R, Garidi, R, Ahmadi, T, Krevvata, M, Zhang, K, de Boer, C, Vara, S, Kampfenkel, T, Vanquickelberghe, V, Vermeulen, J, Avet-Loiseau, H & Sonneveld, P 2021, ' Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 10, pp. 1378-1390 . https://doi.org/10.1016/S1470-2045(21)00428-9
The Lancet. Oncology, Vol. 22, no. 10, p. 1378-1390 (2021)
Background: CASSIOPEIA part 1 showed superior depth of response and significantly improved progression-free survival with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) as induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc1129b347cff7fbfcf632147289e27e
https://pure.eur.nl/en/publications/8f8a69b8-5b29-4b37-a68b-0449871cf60a
https://pure.eur.nl/en/publications/8f8a69b8-5b29-4b37-a68b-0449871cf60a
Autor:
Gertjan J.L. Kaspers, Sonja Zweegman, Johan van Meerloo, Zinia J. Kwidama, Giovanna ter Huizen, Gerrit Jansen, Jacqueline Cloos, Margot S. F. Roeten, Wouter H. Segerink
Publikováno v:
Roeten, M S F, van Meerloo, J, Kwidama, Z J, ter Huizen, G, Segerink, W H, Zweegman, S, Kaspers, G J L, Jansen, G & Cloos, J 2021, ' Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells ', Cells, vol. 10, no. 3, 665, pp. 1-15 . https://doi.org/10.3390/cells10030665
Cells
Volume 10
Issue 3
Cells, 10(3):665, 1-15. MDPI Multidisciplinary Digital Publishing Institute
Cells, Vol 10, Iss 665, p 665 (2021)
Cells
Volume 10
Issue 3
Cells, 10(3):665, 1-15. MDPI Multidisciplinary Digital Publishing Institute
Cells, Vol 10, Iss 665, p 665 (2021)
At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b163b89de767ad688c208c8b46df8a
https://research.vumc.nl/en/publications/9792b04a-da28-4ed2-81d5-a33315fdef31
https://research.vumc.nl/en/publications/9792b04a-da28-4ed2-81d5-a33315fdef31